Cargando…

Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis

Pioglitazone has been reported to increase the risk of bladder cancer but the conclusions of published clinical studies are confusing. We conducted a systematic review and meta-analysis of all eligible randomized controlled trial (RCT) studies and observational studies, in order to identify a more p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Huaqing, Xie, Haiyun, Ying, Yufan, Li, Jiangfeng, Wang, Xiao, Xu, Xin, Zheng, Xiangyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021001/ https://www.ncbi.nlm.nih.gov/pubmed/29970962 http://dx.doi.org/10.2147/CMAR.S164840

Ejemplares similares

Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis
por: Yan, Huaqing, et al.
Publicado: (2018)

METTL3/YTHDF2 m(6)A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer
por: Xie, Haiyun, et al.
Publicado: (2020)

CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo
por: Xu, Xin, et al.
Publicado: (2017)

The dual role of N6‐methyladenosine modification of RNAs is involved in human cancers
por: He, Liujia, et al.
Publicado: (2018)

CCND1, NOP14 and DNMT3B are involved in miR‐502‐5p–mediated inhibition of cell migration and proliferation in bladder cancer
por: Ying, Yufan, et al.
Publicado: (2020)

YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
por: Li, Jiangfeng, et al.
Publicado: (2020)

Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
por: Tang, Huilin, et al.
Publicado: (2018)

Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
por: Xiang, Jianjian, et al.
Publicado: (2019)

Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
por: Filipova, Elena, et al.
Publicado: (2017)

Tomato consumption and prostate cancer risk: a systematic review and meta-analysis
por: Xu, Xin, et al.
Publicado: (2016)

Dysregulation of ncRNAs located at the DLK1‑DIO3 imprinted domain: involvement in urological cancers
por: Li, Jiangfeng, et al.
Publicado: (2019)

The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
por: Song, Sun Ok, et al.
Publicado: (2012)

Hypertension and risk of prostate cancer: a systematic review and meta-analysis
por: Liang, Zhen, et al.
Publicado: (2016)

Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes
por: Qu, Hua, et al.
Publicado: (2017)

circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis
por: Ma, Xueyou, et al.
Publicado: (2021)

Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
por: Yang, Shao-ling, et al.
Publicado: (2018)

Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies
por: Xu, Xin, et al.
Publicado: (2013)

MicroRNA‐501‐3p inhibits the proliferation of kidney cancer cells by targeting WTAP
por: He, Liujia, et al.
Publicado: (2021)

Roles of N(6)‐methyladenosine (m(6)A) RNA modifications in urological cancers
por: Wang, Xiao, et al.
Publicado: (2020)

Pioglitazone, bladder cancer, and detection bias
por: Dolin, Paul
Publicado: (2014)

Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study
por: Gupta, Sunil, et al.
Publicado: (2015)

Pioglitazone Induces Dysplastic Urothelial Changes in Urinary Bladder of Experimental Diabetes
por: Abdel-Hamid, Ahmed A. M., et al.
Publicado: (2021)

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
por: Li, Yan-Rong, et al.
Publicado: (2021)

EGR2-mediated regulation of m(6)A reader IGF2BP proteins drive RCC tumorigenesis and metastasis via enhancing S1PR3 mRNA stabilization
por: Ying, Yufan, et al.
Publicado: (2021)

The Regulatory Role of RNA Metabolism Regulator TDP-43 in Human Cancer
por: Ma, Xueyou, et al.
Publicado: (2021)

Pioglitazone use and risk of bladder cancer: population based cohort study
por: Tuccori, Marco, et al.
Publicado: (2016)

Reduced risk of prostate cancer in childless men as compared to fathers: a systematic review and meta-analysis
por: Mao, Yeqing, et al.
Publicado: (2016)

Pesticide exposure and risk of bladder cancer: A meta-analysis
por: Liang, Zhen, et al.
Publicado: (2016)

Tea consumption and risk of bladder cancer: a meta-analysis
por: Qin, Jie, et al.
Publicado: (2012)

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
por: Neumann, A., et al.
Publicado: (2012)

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
por: Azoulay, Laurent, et al.
Publicado: (2012)

Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study
por: DONG, YOUHONG, et al.
Publicado: (2016)

A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone
por: Agrawal, Prabhat, et al.
Publicado: (2021)

Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Clar, Christine, et al.
Publicado: (2009)

Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs
por: Zhao, Yan, et al.
Publicado: (2022)

SMAD3 and FTO are involved in miR-5581-3p-mediated inhibition of cell migration and proliferation in bladder cancer
por: Sun, Jiazhu, et al.
Publicado: (2022)

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
por: Lewis, James D., et al.
Publicado: (2011)

Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis
por: Wang, Ben, et al.
Publicado: (2018)

Sodium‐glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials
por: Liao, Hung‐Wei, et al.
Publicado: (2018)

Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)
por: Li, Sheyu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tcdu6q9mi07i1s6j7jlv9ai1nt